Applications of Affinity Binding to the Development of Heparin Removing and Sensing Devices
Affinity binding between a specific ligand and a receptor has been widely used in the development of immunoassays, purification of biological materials, and fabrication of biosensors. Because of the high specificity in the interaction between a receptor (e. g., antibody, binding protein, etc.) and its ligand, a sensing or purifying system thus developed would normally possess unique selectivity. In this chapter, we will discuss the applications of the affinity approach to the development of a heparin removal system and two heparin sensing devices (one is a disposable paper strip, and the other is a probe-type heparin electrode). These systems are established utilizing the specific binding of heparin either with its clinical antagonist (i. e., protamine) or with a strong heparin-complexing reagent, tridodecylmethylammonium chloride (TDMAC). These devices should be of significant value because they can improve the safety of current extracorporeal blood circulation (ECBC) procedures or provide a safeguard to heparin therapy.
KeywordsCellulose Migration Catheter Citrate Epoxy
Unable to display preview. Download preview PDF.
- Diederich, D A., Wiegmann, T. B., and Pinnick, R. V., 1985, Method for regional anticoagulation during extracorporeal dialysis. U.S. Patent 4,500,309.Google Scholar
- Hartman, K., Luterotti, S., Osswald, H. F., Oehme, M., Meier, P. C., Ammann, D., and Simon, W., 1978, Chloride-selective liquid-membrane electrodes based on lipophilic methyl-tri-N-alkylammonium compounds and their applicability to blood serum measurements, Mikrochim. Acta 11:235–244.CrossRefGoogle Scholar
- Hirsh, J., 1984, Heparin induced bleeding, Nouv. Rev. Fr. Hematol. 26:262–266.Google Scholar
- Jaques, L. B., 1980, Heparins: Anionic polyelectrolyte drugs, Pharmacol. Rev. 31:99–165.Google Scholar
- Katz, N. M., Kim, Y. D., Siegelman, R., Ved, S. A., Ahned, S. W., and Wallace, R. B., 1987, Hemodynamics of protamine administration, J. Thoracic Cardiovasc. Surg. 94:881–886.Google Scholar
- Kelton, J. G., and Hirsh, J., 1984, Bleeding associated with antithrombotic therapy, Semin. Hematol. 17:375–379.Google Scholar
- Kirklin, J. K., Chenoweth, D. E., Naftel, D. C., Blackstone, E. H., Kirklin, J. W., Bitran, D. D., Curd, J. G., Reves, J. G., and Samuelson, P. N., 1986, Effects of protamine administration after cardiopulmonary bypass on complement, blood components, and the hemodynamic state, Ann. Thoracic Surg. 41:193–199.CrossRefGoogle Scholar
- Nojiri, C., Park, K. D., and Grainger, D. W., 1990, In vitro nonthrombogenicity of heparin immobilized polymer surfaces, Trans. Am. Soc. Artif. Intern. Organs 36:168–172.Google Scholar
- Weiler, J. M., Freiman, P., Sharath, M. D., Metzger, W. J., Smith, J. M., Richerson, H. B., Ballas, Z. K., Halverson, P. C., Shulan, D. D. J., Matsuo, S., and Wilson, R. L., 1985, Serious adverse reactions to protamine sulfate: Are alternatives needed? J. Allergy Clin. Immunol. 75:297–303.PubMedCrossRefGoogle Scholar
- Weiler, J. M., Cellhaus, M. A., Carter, J. G., Meng, R. L., Benson, P. M., Hottel, R. A., Schillig, K. B., Vegh, A.B., and Clarke, W. R., 1990. A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery, J. Allergy Clin. Immunol. 85:713–719.PubMedCrossRefGoogle Scholar
- Yang, V. C., 1989, Extracorporeal blood deheparinization system, U.S. Patent 4,800,016.Google Scholar